CHS Pharma Inc. (CHS) is a Biotechnology Development Company located in South Florida. CHS owns an Intellectual property portfolio for potential treatments related to Ischemic Stroke, Dry Macular Degeneration as well as other age related disorders such as Alzheimer’s disease. These technologies were developed by Dr. Jang-Yen Wu, Dr. Howard Prentice and their colleagues. Dr. Wu is a Senior Fellow and Distinguished Professor at Florida Atlantic University’s Charles E. Schmidt College of Medicine. Dr. Prentice is a Professor of Biomedical Science in the Charles E. Schmidt College of Medicine. Dr. Wu has published more than 300 papers in journals such as Science, Nature, PNAS, among others. He has made a great impact in biomedical sciences, particularly in basic and translational neuroscience, and is recognized as one of the most cited scientists in the world identified by Current Contents/ISI (2002). In translational neuroscience, Dr. Wu and his team have developed several mechanism-based treatments for neurodegenerative diseases including Parkinson’s disease, Ischemic Stroke, Alzheimer’s disease and Epilepsy. His inventions are quite novel and several patents have been awarded to him and his team. Dr. Prentice has over 70 publications in numerous journals including PNAS, EMBO Journal, Cell, Molecular Neurobiology, and Molecular and Cell Biology. Dr. Prentice’s principal research interests are in tissue hypoxia and ischemia and in molecular pathways of neuroprotection in stroke therapy.

Patents 18show all

  • 16
    A61K - Preparations for medical, dental, or toilet purposes
  • 2
    C07C - Acyclic or carbocyclic compounds
  • 2
    C07D - Heterocyclic compounds
  • 2
    C07K - Peptides
  • 2
    Y02A - Technologies for adaptation to climate change

Contact Information

500 Maplewood Dr #5a
Jupiter, FL 33458
United States

Overview

Total FundingEmployeesLast Funding DateStatus
unknownOperating